Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

SANTINI, Daniele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.105
AS - Asia 1.251
EU - Europa 881
SA - Sud America 228
AF - Africa 41
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 1
Totale 6.511
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.085
SG - Singapore 559
CN - Cina 350
IT - Italia 240
BR - Brasile 175
DE - Germania 133
HK - Hong Kong 117
RU - Federazione Russa 117
GB - Regno Unito 77
VN - Vietnam 70
PL - Polonia 58
SE - Svezia 43
IE - Irlanda 42
FR - Francia 41
FI - Finlandia 38
KR - Corea 25
IN - India 24
AR - Argentina 18
TR - Turchia 17
AT - Austria 16
UA - Ucraina 16
EC - Ecuador 15
JP - Giappone 15
ES - Italia 13
IR - Iran 13
NL - Olanda 13
CA - Canada 12
BD - Bangladesh 10
RO - Romania 10
MA - Marocco 9
ZA - Sudafrica 9
UZ - Uzbekistan 8
BE - Belgio 7
CI - Costa d'Avorio 7
IQ - Iraq 7
VE - Venezuela 7
EG - Egitto 6
AE - Emirati Arabi Uniti 5
MX - Messico 5
PK - Pakistan 5
CO - Colombia 4
ID - Indonesia 4
KE - Kenya 4
LT - Lituania 4
AL - Albania 3
BH - Bahrain 3
CL - Cile 3
MY - Malesia 3
NP - Nepal 3
PY - Paraguay 3
BG - Bulgaria 2
ET - Etiopia 2
JO - Giordania 2
LB - Libano 2
OM - Oman 2
PT - Portogallo 2
SA - Arabia Saudita 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AU - Australia 1
AZ - Azerbaigian 1
BO - Bolivia 1
CH - Svizzera 1
CR - Costa Rica 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EU - Europa 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
LU - Lussemburgo 1
MD - Moldavia 1
MN - Mongolia 1
PE - Perù 1
PS - Palestinian Territory 1
SX - ???statistics.table.value.countryCode.SX??? 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
TZ - Tanzania 1
UY - Uruguay 1
Totale 6.511
Salva come PNG Salva come JPEG
Città #
Fairfield 750
Ashburn 542
Woodbridge 346
Singapore 306
Houston 288
Seattle 287
Wilmington 256
Cambridge 225
Chandler 217
Hong Kong 117
Ann Arbor 116
Beijing 72
Medford 67
Altamura 59
Moscow 52
Chicago 47
Los Angeles 46
Zgierz 45
Dublin 42
Lawrence 42
Princeton 42
Des Moines 39
Hefei 34
London 34
Dearborn 33
Nanjing 32
Palermo 31
San Diego 30
Ludwigshafen am Rhein 27
Santa Clara 27
Helsinki 24
New York 24
Phoenix 22
Salt Lake City 22
Seoul 22
São Paulo 21
Dallas 20
Frankfurt am Main 20
Ho Chi Minh City 20
Hanoi 19
Berlin 18
The Dalles 18
Rome 16
Shenyang 16
Buffalo 15
Elk Grove Village 15
Nanchang 15
Boardman 14
Changsha 14
Jinan 13
San Paolo di Civitate 13
Tokyo 13
Nuremberg 12
Brooklyn 11
Hebei 11
Izmir 11
Tampa 10
Tianjin 10
Denver 9
Milan 9
Tehran 9
Chennai 8
Tulsa 8
Warsaw 8
Abidjan 7
Amsterdam 7
Brussels 7
Hangzhou 7
Redwood City 7
Cairo 6
Da Nang 6
Guangzhou 6
Guayaquil 6
Jiaxing 6
Lauterbourg 6
Vienna 6
Düsseldorf 5
Falkenstein 5
Haiphong 5
Johannesburg 5
Lucera 5
Montreal 5
Orange 5
Orem 5
Saint Petersburg 5
Sterling 5
Stockholm 5
Turin 5
Zhengzhou 5
Atlanta 4
Cape Town 4
Detroit 4
Forest City 4
Jacksonville 4
Kitzingen 4
Mehlingen 4
Messina 4
Miami 4
Nairobi 4
Ningbo 4
Totale 4.947
Salva come PNG Salva come JPEG
Nome #
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials 263
Update on capecitabine alone and in combination regimens in colorectal cancer patients 247
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 229
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 227
Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma 222
Lack of Correlation between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: A Retrospective Study 212
Cetuximab in small bowel adenocarcinoma: A new friend 202
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 196
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis 194
Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib. 193
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases 192
A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC) 189
Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? 188
Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions 185
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 182
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 178
Deregulation of dicer and mir-155 expression in liposarcoma 173
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 170
New molecular targets in bone metastases 161
Hepatocellular carcinoma treatment over sorafenib: Epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? 158
Use of the word “cured” for cancer patients—implications for patients and physicians: The Siracusa charter 155
Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting 153
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 151
Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules 147
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: A new pharmacodynamic marker? 140
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 136
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 134
The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma 130
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 128
Pharmacogenomics of cetuximab in metastatic colorectal carcinoma 127
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials 119
Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary 115
Recent advances in desmoid tumor therapy 112
Management of orphan symptoms: ESMO Clinical Practice Guidelines for diagnosis and treatment † 111
Corrigendum to "Liquid biopsies in lung cancer: The new ambrosia of researchers" [Biochem. Biophys. Act. 1846(2014) 539-546] 110
The use of same in chemotherapy-induced liver injury 104
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies 91
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 89
On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study. 87
Antitumor effect of cabozantinib in bone metastatic models of renal cell carcinoma 83
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 77
S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Patients Undergoing Oxaliplatin-Based Chemotherapy Regimens 77
Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas 76
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas 74
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 58
Small bowel carcinomas in celiac or Crohn's disease: Distinctive histophenotypic, molecular and histogenetic patterns 38
null 3
Totale 6.786
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.638
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.638
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021413 0 0 0 0 0 27 52 57 53 99 68 57
2021/2022555 32 123 25 13 8 17 25 38 45 69 79 81
2022/2023691 64 173 14 51 62 96 29 64 77 6 37 18
2023/2024270 20 30 32 15 17 33 35 9 2 4 3 70
2024/20251.044 14 85 46 47 23 56 63 103 57 114 240 196
2025/20261.274 274 104 179 223 360 134 0 0 0 0 0 0
Totale 6.786